The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
about
Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trialsAspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American CoReview of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryAspirin in the Chemoprevention of Colorectal Neoplasia: An OverviewAntiplatelet agents for intermittent claudicationStandards of medical care in diabetes--2012Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsAspirin for primary prevention of cardiovascular diseasePeripheral Arterial Disease in Patients with Type 2 Diabetes MellitusComparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-AnalysisA systematic review of aspirin in primary prevention: is it time for a new approach?Comparative effectiveness review of antiplatelet agents in peripheral artery diseaseUpdate on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuStatins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trialStandards of medical care in diabetes--2013Recommending aspirin for primary prevention in diabetic patients: what may we conclude from the data?Cardiovascular Disease in Women: Clinical Perspectives.The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitusAspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.Standards of medical care in diabetes--2010.Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study.Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization.Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society.Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes.A retrospective cohort study on the risk of stroke in relation to a priori health knowledge level among people with type 2 diabetes mellitus in Taiwan.Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialAspirin for primary cardiovascular prevention: when is it worth the risks?Inflammation and the osteogenic regulation of vascular calcification: a review and perspective.Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia.Current status of prescription in type 2 diabetic patients from general hospitals in busan.Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysisCost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.Thromboxane and the thromboxane receptor in cardiovascular disease.Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?Peripheral artery disease: current insight into the disease and its diagnosis and management.
P2860
Q21132402-76E23F87-8B88-4958-AA91-A6D6C3A13F5CQ22241289-5813D985-6161-4635-B568-33853462BF0EQ22241777-053F974A-3AB1-4F45-966B-8DAA3FEAD15FQ22241786-6AE934E2-77BD-4F99-9AB8-9CB38BAEDC42Q22306433-7E5B8CBC-BB9C-40E4-BC95-E54DB9BFF286Q24235178-A8FBE78B-3409-4DEC-B7CC-AB9B5CDE4092Q24632533-D1CB402B-99AC-48BA-994E-47ACA71A3351Q24645391-100BE560-746F-4B84-B960-E4698DFDBBCEQ26774150-0669DAB4-48AA-419B-A724-A91D4BD570A7Q26795374-8DD54C81-267E-4208-8A32-5FC18652C43EQ26798134-DB516D4D-7E80-4396-A135-30048C3C0A65Q26864015-715604D1-1F08-41E5-B6AD-40862DED28A7Q27023150-0311E866-E441-47AD-A32D-F962FC33AE1FQ27687851-6C99118D-E492-45A8-A71E-22A52F907675Q28249469-C128EA19-3C61-49DE-AAE4-1583D1736A5BQ28481709-001FC307-1642-4B0A-BE11-9D39EB1F1C9EQ29620309-6E5F476D-5CBE-469A-AA86-3172F54EFC6CQ30582282-F71F8B24-23B4-492D-A112-6E46CF524AFEQ30743765-BE05713C-4743-47C1-A8A1-D81C1023C1F5Q33405692-B3F2B722-F632-4DB2-AB35-62323B807AF2Q33501445-5D3CA618-EE78-4472-ACF2-C9DDAE5B3929Q33515541-F7FEF9CC-CC06-4E0E-B3FB-25B48E60D0AFQ33554238-079ABA41-3FDF-4A54-953D-4953D59E297EQ33558386-B69C08B1-FD2F-4532-8D58-281BC28A1DFBQ33602214-7CE8D348-5203-4285-88D2-F2043243F4DFQ33627687-A801602A-3DA7-49D3-8019-A0E9AFFCAABFQ33647298-A0AB4CC9-740A-4857-96D2-A382B3C979CAQ33706621-65343A52-946B-4085-BABF-1A3CACDE5140Q33709160-16123B1D-FC31-4DAC-B178-A3583D58D4F5Q33716777-E6687D04-20EF-4340-9A4B-4B56207FEE19Q33751427-C18D8F57-F97A-4A48-8987-D80074868809Q33774734-2621F3A2-D4D9-4DAD-BD02-2B0113ED5744Q33782750-A7C26F10-F388-46BD-8771-A3F609540BB8Q33804396-8968AB00-72FE-4774-AD80-8E8E897DE3C0Q33850338-06E8B54C-EDFF-4550-B418-B70EDC7ECD09Q33859058-601B44DF-C195-4799-8388-C76917D9729FQ33873025-C1D55AB2-F174-40CA-82D7-92121530AADDQ33899567-DD643919-A3DF-4C39-8F83-828F53D83827Q33949522-44A9ECA6-BB45-4151-B8E8-CAB9C6AF2CB6Q33951581-2DC9D64E-1C83-43F0-9F2E-343796E47366
P2860
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The prevention of progression ...... c peripheral arterial disease.
@en
The prevention of progression of arterial disease and diabetes
@nl
type
label
The prevention of progression ...... c peripheral arterial disease.
@en
The prevention of progression of arterial disease and diabetes
@nl
prefLabel
The prevention of progression ...... c peripheral arterial disease.
@en
The prevention of progression of arterial disease and diabetes
@nl
P2093
P2860
P921
P356
P1433
P1476
The prevention of progression ...... ic peripheral arterial disease
@en
P2093
Alan Connacher
Andrew Jamieson
Andrew Morris
Angus MacCuish
Christopher Kelly
Colin Semple
David Matthews
Derek Gordon
Diabetes Registry Group
Graeme Leese
P2860
P356
10.1136/BMJ.A1840
P407
P577
2008-10-16T00:00:00Z